- Home
- FIVN vs EYPT Comparison
FIVN vs EYPT Comparison
Compare FIVN & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIVN | EYPT |
|---|---|---|
| Founded | 2001 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2014 | 2005 |
Fundamental Metrics
Financial Performance| Metric | FIVN | EYPT |
|---|---|---|
| Price | $20.87 | $13.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | $26.06 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 3.4M | 785.8K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 364.71 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,149,088,000.00 | $7,539,000.00 |
| Revenue This Year | $11.39 | N/A |
| Revenue Next Year | $10.00 | $3,115.57 |
| P/E Ratio | $99.24 | ★ N/A |
| Revenue Growth | ★ 10.28 | N/A |
| 52 Week Low | $13.29 | $5.46 |
| 52 Week High | $30.35 | $19.11 |
Technical Indicators
Market Signals| Indicator | FIVN | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 60.82 | 48.30 |
| Support Level | $20.49 | $13.61 |
| Resistance Level | $22.08 | $14.74 |
| Average True Range (ATR) | 1.47 | 0.76 |
| MACD | 0.30 | 0.02 |
| Stochastic Oscillator | 57.14 | 52.09 |
Price Performance
Historical ComparisonAbout FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.